Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
Modification of the duocarmycin pharmacophore enables CYP1A1 targeting for biological activity. [electronic resource] by
- Pors, Klaus
- Loadman, Paul M
- Shnyder, Steven D
- Sutherland, Mark
- Sheldrake, Helen M
- Guino, Meritxell
- Kiakos, Konstantinos
- Hartley, John A
- Searcey, Mark
- Patterson, Laurence H
Producer: 20120227
In:
Chemical communications (Cambridge, England) vol. 47
Availability: No items available.
|
|
12.
|
Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. [electronic resource] by
- Travica, Sandra
- Pors, Klaus
- Loadman, Paul M
- Shnyder, Steven D
- Johansson, Inger
- Alandas, Mohammed N
- Sheldrake, Helen M
- Mkrtchian, Souren
- Patterson, Laurence H
- Ingelman-Sundberg, Magnus
Producer: 20140108
In:
Clinical cancer research : an official journal of the American Association for Cancer Research vol. 19
Availability: No items available.
|
|
13.
|
Exploration of [2 + 2 + 2] cyclotrimerisation methodology to prepare tetrahydroisoquinoline-based compounds with potential aldo-keto reductase 1C3 target affinity. [electronic resource] by
- Santos, Ana R N
- Sheldrake, Helen M
- Ibrahim, Ali I M
- Danta, Chhanda Charan
- Bonanni, Davide
- Daga, Martina
- Oliaro-Bosso, Simonetta
- Boschi, Donatella
- Lolli, Marco L
- Pors, Klaus
Publication details: MedChemComm Aug 2019
In:
MedChemComm vol. 10
Availability: No items available.
|
|
14.
|
Antitumor activity of a duocarmycin analogue rationalized to be metabolically activated by cytochrome P450 1A1 in human transitional cell carcinoma of the bladder. [electronic resource] by
- Sutherland, Mark
- Gill, Jason H
- Loadman, Paul M
- Laye, Jonathan P
- Sheldrake, Helen M
- Illingworth, Nicola A
- Alandas, Mohammed N
- Cooper, Patricia A
- Searcey, Mark
- Pors, Klaus
- Shnyder, Steve D
- Patterson, Laurence H
Producer: 20130627
In:
Molecular cancer therapeutics vol. 12
Availability: No items available.
|
|
15.
|
Re-engineering of the duocarmycin structural architecture enables bioprecursor development targeting CYP1A1 and CYP2W1 for biological activity. [electronic resource] by
- Sheldrake, Helen M
- Travica, Sandra
- Johansson, Inger
- Loadman, Paul M
- Sutherland, Mark
- Elsalem, Lina
- Illingworth, Nicola
- Cresswell, Alexander J
- Reuillon, Tristan
- Shnyder, Steven D
- Mkrtchian, Souren
- Searcey, Mark
- Ingelman-Sundberg, Magnus
- Patterson, Laurence H
- Pors, Klaus
Producer: 20131111
In:
Journal of medicinal chemistry vol. 56
Availability: No items available.
|